TNF- α and microalbuminuria in patients with type 2 diabetes mellitus

Journal of Diabetes Research

Volumn 2014, Issue , 2014, Pages

  Lampropoulou, I Th ^a   Stangou, M ^a   Papagianni, A ^a   Didangelos, T ^a   Iliadis, F ^a   Efstratiadis, G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; URINALYSIS; ALBUMINURIA; BLOOD; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; URINE;

ADULT; AGED; ALBUMINURIA; BIOMARKERS; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; URINALYSIS;

EID: 84920527810     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2014/394206     Document Type: Article

References (37)

1. M. E. Molitch, R. A. DeFronzo, M. J. Franz et al. , "Nephropathy in diabetes, " Diabetes Care, vol. 27, supplement 1, pp. s79-s83, 2004.
2. KDOQI, "Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease, " American Journal of Kidney Diseases, vol. 49, supplement 2, pp. S12-S154, 2007.
3. C. W. Heilig, L. A. Concepcion, B. L. Riser et al. , "Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype, " The Journal of Clinical Investigation, vol. 96, no. 4, pp. 1802-1814, 1995.
4. M. E. Cooper, "Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy, " Diabetologia, vol. 44, no. 11, pp. 1957-1972, 2001.
5. E. D. Schleicher and C. Weigert, "Role of the hexosamine biosynthetic pathway in diabetic nephropathy, " Kidney International, Supplement, vol. 58, no. 77, pp. S13-S18, 2000.
6. M. Brownlee, "Biochemistry and molecular cell biology of diabetic complications, " Nature, vol. 414, no. 6865, pp. 813-820, 2001.
7. S.-Y. Goh and M. E. Cooper, "The role of advanced glycation end products in progression and complications of diabetes, "The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 4, pp. 1143-1152, 2008.
8. Z. Makita, S. Radoff, E. J. Rayfield et al. , "Advanced glycosylation end products in patients with diabetic nephropathy, " The New England Journal of Medicine, vol. 325, no. 12, pp. 836-842, 1991.
9. S. T. Crowley, M. Brownlee, D. Edelsteinet al. , "Effectsofnonenzymatic glycosylation of mesangial matrix on proliferation of mesangial cells, " Diabetes, vol. 40, no. 5, pp. 540-547, 1991.
10. S.-I. Yamagishi and T. Matsui, "Advanced glycation end products, oxidative stress and diabetic nephropathy, " Oxidative Medicine and Cellular Longevity, vol. 3, no. 2, pp. 101-108, 2010.
11. J. L. Wautier and P. J. Guillausseau, "Advanced glycation end products, their receptors and diabetic angiopathy, " Diabetes and Metabolism, vol. 27, no. 5, pp. 535-542, 2001.
12. H. Makino, M. Haneda, T. Babazono et al. , "Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes, " Diabetes Care, vol. 30, no. 6, pp. 1577-1578, 2007.
13. J. M. Forbes, M. T. Coughlan, and M. E. Cooper, "Oxidative stress as amajor culprit in kidney disease in diabetes, " Diabetes, vol. 57, no. 6, pp. 1446-1454, 2008.
14. J. F. Navarro-Gonźalez, C. Mora-Ferńandez, M. M. de Fuentes, and J. Garćia-Perez, "Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy, " Nature Reviews Nephrology, vol. 7, no. 6, pp. 327-340, 2011.
15. A. Rivero, C. Mora, M. Muros, J. Garćia, H. Herrera, and J. F. Navarro-Gonźalez, "Pathogenic perspectives for the role of inflammation in diabetic nephropathy, " Clinical Science, vol. 116, no. 6, pp. 479-492, 2009.
16. J. F. Navarro-Gonźalez and C. Mora-Ferńandez, "The role of inflammatory cytokines in diabetic nephropathy, " Journal of the American Society ofNephrology, vol. 19, no. 3, pp. 433-442, 2008.
17. J. F. Navarro, C. Mora, M. Gomez, M. Muros, C. Ĺopez-Aguilar, and J. Garćia, "Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-α and interleukin-6 in type 2 diabetic patients, " Nephrology Dialysis Transplantation, vol. 23, no. 3, pp. 919-926, 2008.
18. T. Nakamura, M. Fukui, I. Ebihara et al. , "mRNA expression of growth factors in glomeruli from diabetic rats, " Diabetes, vol. 42, no. 3, pp. 450-456, 1993.
19. J. F. Navarro, F. J. Milena, C. Mora et al. , "Tumor necrosis factor-α gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition, " Kidney International, vol. 68, no. 99, pp. S-98-S-102, 2005.
20. J. F. Navarro, C. Mora, M. Maćia, and J. Garćia, "Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus, " American Journal of Kidney Diseases, vol. 42, no. 1, pp. 53-61, 2003.
21. J. Lin, F. B. Hu, C. Mantzoros, and G. C. Curhan, "Lipid and inflammatory biomarkers and kidney function decline in type 2 diabetes, " Diabetologia, vol. 53, no. 2, pp. 263-267, 2010.
22. UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose controlwith sulphonylureas or insulin compared with conventional treatment and risk of complications in patientswith type 2 diabetes (UKPDS 33), " The Lancet, vol. 352, no. 9131, pp. 837-853, 1998.
23. K. L. Ma, Y. Zhang, J. Liu et al. , "Establishment of an inflamed animal model of diabetic nephropathy, " International Journal of Biological Sciences, vol. 10, no. 2, pp. 149-159, 2014.
24. C. Sassy-Prigent, D. Heudes, C. Mandet et al. , "Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats, " Diabetes, vol. 49, no. 3, pp. 466-475, 2000.
25. N. Choudhary and R. S. Ahlawat, "Interleukin-6 and C-reactive protein in pathogenesis of diabetic nephropathy: new evidence linking inflammation, glycemic control, and microalbuminuria, " Iranian Journal of Kidney Diseases, vol. 2, no. 2, pp. 72-79, 2008.
26. M. A. Niewczas, L. H. Ficociello, A. C. Johnson et al. , "Serum concentrations of markers of TNFα andFas-mediatedpathways and renal function in nonproteinuric patients with type 1 diabetes, " Clinical Journal of the American Society of Nephrology, vol. 4, no. 1, pp. 62-70, 2009.
27. R. L. Klein, S. J. Hunter, A. J. Jenkins et al. , "Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort, " Diabetes Care, vol. 26, no. 5, pp. 1439-1448, 2003.
28. A. Corti, F. DAmbrosio, M. Marino, S. Merli, and G. Cassani, "Identification of differentially glycosylated forms of the soluble p75 tumor necrosis factor (TNF) receptor in human urine, " European Cytokine Network, vol. 6, no. 1, pp. 29-35, 1995.
29. W. Bao, D. Min, S. M. Twigg et al. , "Monocyte CD147 is induced by advanced glycation end products and high glucose concentration: Possible role in diabetic complications, " American Journal of Physiology-Cell Physiology, vol. 299, no. 5, pp. C1212-C1219, 2010.
30. K. Mastej and R. Adamiec, "Neutrophil surface expression of CD11b and CD62L in diabetic microangiopathy, " Acta Diabetologica, vol. 45, no. 3, pp. 183-190, 2008.
31. J. F. Navarro-Gonźalez, A. Jarque, M. Muros, C. Mora, and J. Garćia, "Tumor necrosis factor-α as a therapeutic target for diabetic nephropathy, "CytokineandGrowthFactorReviews, vol. 20, no. 2, pp. 165-173, 2009.
32. Y. Moriwaki, T. Yamamoto, Y. Shibutani et al. , "Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetesmellitus: relationship with diabetic nephropathy, " Metabolism: Clinical and Experimental, vol. 52, no. 5, pp. 605-608, 2003.
33. J. Wu, Y. Ding, C. Zhu et al. , "Urinary TNF-α and NGAL are correlated with the progression of nephropathy in patients with type 2 diabetes, " Experimental andTherapeuticMedicine, vol. 6, no. 6, pp. 1482-1488, 2013.
34. K. Kalantarinia, A. S. Awad, and H. M. Siragy, "Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats, " Kidney International, vol. 64, no. 4, pp. 1208-1213, 2003.
35. K. Omote, T. Gohda, M. Murakoshi et al. , "Role of the TNF pathway in the progression of diabetic nephropathy in KK-Ay mice, " American Journal of Physiology: Renal Physiology, vol. 306, no. 11, pp. F1335-F1347, 2014.
36. Z. Wang, M. Wei, M. Wang et al. , "Inhibition of macrophage migration inhibitory factor reduces diabetic nephropathy in type II diabetes mice, " Inflammation, 2014.
37. J. F. Navarro-Gonźalez, C. Mora-Ferńandez, M. M. de Fuentes et al. , "Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial, " Journal of the American Society of Nephrology, 2014.